Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Rating of “Buy” by Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have earned a consensus rating of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $63.33.

ESTA has been the subject of a number of analyst reports. Stephens reaffirmed an “overweight” rating and issued a $47.00 price target on shares of Establishment Labs in a report on Thursday, January 11th. Mizuho raised their price target on Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. JPMorgan Chase & Co. lifted their target price on Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, Citigroup lifted their price target on shares of Establishment Labs from $49.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday.

Establishment Labs Price Performance

ESTA stock opened at $54.16 on Friday. The company has a debt-to-equity ratio of 10.26, a quick ratio of 1.67 and a current ratio of 3.06. The company’s fifty day moving average price is $44.28 and its 200-day moving average price is $35.99. Establishment Labs has a one year low of $16.96 and a one year high of $79.88. The company has a market capitalization of $1.47 billion, a PE ratio of -17.82 and a beta of 1.24.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Wednesday, February 28th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. The company had revenue of $31.60 million for the quarter, compared to the consensus estimate of $31.44 million. During the same period in the previous year, the business earned ($0.55) earnings per share. The firm’s revenue for the quarter was down 27.9% on a year-over-year basis. On average, equities analysts anticipate that Establishment Labs will post -1.58 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

Hedge funds have recently bought and sold shares of the stock. Brown Advisory Inc. raised its holdings in Establishment Labs by 63.9% in the fourth quarter. Brown Advisory Inc. now owns 2,428,792 shares of the company’s stock worth $62,881,000 after purchasing an additional 946,612 shares in the last quarter. Findell Capital Management LLC bought a new position in shares of Establishment Labs during the 4th quarter worth approximately $14,680,000. Fourth Sail Capital LP purchased a new stake in Establishment Labs during the fourth quarter valued at approximately $14,473,000. Millennium Management LLC boosted its stake in Establishment Labs by 2,021.2% in the second quarter. Millennium Management LLC now owns 419,059 shares of the company’s stock valued at $22,788,000 after acquiring an additional 399,303 shares in the last quarter. Finally, Cowen AND Company LLC grew its holdings in Establishment Labs by 18.1% in the third quarter. Cowen AND Company LLC now owns 1,141,172 shares of the company’s stock worth $55,997,000 after purchasing an additional 175,000 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.